AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
PORT WASHINGTON, N.Y., April 07, 2016 -- ACETO Corporation (NASDAQ:ACET), an international company engaged in the marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Salvatore Guccione, President and CEO, will present at the Needham & Company Healthcare Conference on April 12, 2016 at 5:00 pm ET at the Westin New York Grand Central Hotel.
A webcast of the presentation will be available under Events and Presentations in the investor relations section of the company’s website at www.aceto.com or http://wsw.com/webcast/needham76/acet.
ABOUT ACETO
ACETO Corporation, incorporated in 1947 and with offices and operations in 10 countries, is engaged in the marketing, sale and distribution of Human Health products (finished dosage form generics and nutritional products), Pharmaceutical Ingredients (pharmaceutical intermediates and active pharmaceutical ingredients) and Performance Chemicals (specialty chemicals and agricultural protection products).
Investor Relations Contact: LHA Jody Burfening [email protected] (212) 838-3777
